Clinical trialNo phase (not a drug trial)Withdrawn
A Pilot Study to Evaluate the Efficacy of ITDD vs. CMM in the Treatment of Pancreatic Cancer Pain
- Outcome
- Stopped earlyThe study was never initiated by sponsor. Patients where never recruited. (Enrollment)
- Phase
- No phase (not a drug trial)
- Status
- Withdrawn
- Study type
- Interventional
- Planned start
- April 2016
- Planned end
- September 2018
- Enrollment
- 0 participants
- Sites
- 1
- Primary outcomes
- Visual Analog Scale Pain Scores
- Sponsor type
- Industry
- Results posted
- No
- Last update
- 15 February 2019
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The purpose of this study is to compare efficacy of pain treatment with ITDD to efficacy of pain treatment with CMM in patients with pancreatic cancer pain.
Detailed description public domain (ClinicalTrials.gov)
This study is a non-randomized, open-label, single-center study that will compare efficacy of pain treatment with ITDD to efficacy of pain treatment with CMM in patients suffering from pancreatic cancer pain. There will be two treatment groups: Study group (ITDD): These subjects will have a Prometra System implanted and managed with the appropriate drug regimen to treat their pain. Systemic analgesics will not be prescribed for this group. Control group (CMM): These subjects will be treated with CMM to treat their pain. A maximum of 30 subjects (maximum of 15 in each treatment group) may be enrolled in this study at one study center.